H

Hans Biomed Corp
KOSDAQ:042520

Watchlist Manager
Hans Biomed Corp
KOSDAQ:042520
Watchlist
Price: 30 100 KRW Market Closed
Market Cap: 407.3B KRW

Wall Street
Price Targets

Price Targets Summary
Hans Biomed Corp

There are no price targets for Hans Biomed Corp.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Hans Biomed Corp Competitors:
Price Targets
688382
InventisBio Co Ltd
73% Upside
300676
BGI Genomics Co Ltd
28% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
48% Upside
IONS
Ionis Pharmaceuticals Inc
9% Upside
MSB
Mesoblast Ltd
22% Upside
ELDN
Eledon Pharmaceuticals Inc
410% Upside
096530
Seegene Inc
76% Upside
RCUS
Arcus Biosciences Inc
42% Upside

Revenue
Forecast

Revenue Estimate
Hans Biomed Corp

For the last 12 years the compound annual growth rate for Hans Biomed Corp's revenue is 14%. The projected CAGR for the next 2 years is 19%.

14%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Hans Biomed Corp

For the last 12 years the compound annual growth rate for Hans Biomed Corp's operating income is -13%. The projected CAGR for the next 2 years is 281%.

-13%
Past Growth
281%
Estimated Growth
Estimates Accuracy
-10%
Average Miss

Net Income
Forecast

Net Income Estimate
Hans Biomed Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Hans Biomed Corp's stock price target?
Not Available

Hans Biomed Corp doesn't have any price targets made by Wall Street professionals.

What is Hans Biomed Corp's Revenue forecast?
Projected CAGR
19%

For the last 12 years the compound annual growth rate for Hans Biomed Corp's revenue is 14%. The projected CAGR for the next 2 years is 19%.

What is Hans Biomed Corp's Operating Income forecast?
Projected CAGR
281%

For the last 12 years the compound annual growth rate for Hans Biomed Corp's operating income is -13%. The projected CAGR for the next 2 years is 281%.

Back to Top